85
Participants
Start Date
October 10, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
2.5 μg InvaplexAR-Detox
2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
10 μg InvaplexAR-Detox
10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.
0.1 μg of dmLT
0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).
Placebo
Placebo vaccination with commercially available saline solution.
RECRUITING
Leiden University Medical Center, Leiden
Centre for Infectious Disease Research in Zambia
OTHER
PATH
OTHER
Walter Reed Army Institute of Research (WRAIR)
FED
Göteborg University
OTHER
European Vaccine Initiative
OTHER
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Leiden University Medical Center
OTHER